JungAh Jung

442 total citations
12 papers, 324 citations indexed

About

JungAh Jung is a scholar working on Cell Biology, Oncology and Molecular Biology. According to data from OpenAlex, JungAh Jung has authored 12 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cell Biology, 5 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in JungAh Jung's work include Microtubule and mitosis dynamics (6 papers), Acute Myeloid Leukemia Research (2 papers) and Tryptophan and brain disorders (2 papers). JungAh Jung is often cited by papers focused on Microtubule and mitosis dynamics (6 papers), Acute Myeloid Leukemia Research (2 papers) and Tryptophan and brain disorders (2 papers). JungAh Jung collaborates with scholars based in United States, Spain and France. JungAh Jung's co-authors include Howard Fingert, E. Jane Leonard, Karthik Venkatakrishnan, Josep Tabernero, Élena Elez, José Alejandro Pérez Fidalgo, Jeffrey Ecsedy, Adelaida Piera, Arnaud Pigneux and Pierre Fenaux and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Psychiatry.

In The Last Decade

JungAh Jung

12 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JungAh Jung United States	8	158	140	107	59	49	12	324
Vita Direnzo Italy	14	17 0.1×	73 0.5×	84 0.8×	84 1.4×	38 0.8×	22	388
Anna Petroccione Italy	6	61 0.4×	77 0.6×	85 0.8×	26 0.4×	6 0.1×	13	233
Douglas S. Barker United States	7	140 0.9×	92 0.7×	251 2.3×	18 0.3×	10 0.2×	9	371
Matthias Schranzhofer Austria	10	68 0.4×	20 0.1×	253 2.4×	36 0.6×	194 4.0×	20	491
Padmaja Yerramilli-Rao United States	10	29 0.2×	90 0.6×	145 1.4×	110 1.9×	16 0.3×	15	349
Simone Münst Switzerland	4	17 0.1×	130 0.9×	104 1.0×	7 0.1×	5 0.1×	4	329
Brittany Bahamón United States	8	23 0.1×	72 0.5×	159 1.5×	12 0.2×	5 0.1×	14	254
Lan Pham United States	7	14 0.1×	36 0.3×	109 1.0×	31 0.5×	50 1.0×	17	217
Elizabeth Phillips United States	8	103 0.7×	18 0.1×	157 1.5×	10 0.2×	11 0.2×	10	378
Victoria Gennaro United States	5	34 0.2×	77 0.6×	163 1.5×	34 0.6×	5 0.1×	5	282

Countries citing papers authored by JungAh Jung

Since Specialization

Citations

This map shows the geographic impact of JungAh Jung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JungAh Jung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JungAh Jung more than expected).

Fields of papers citing papers by JungAh Jung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JungAh Jung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JungAh Jung. The network helps show where JungAh Jung may publish in the future.

Co-authorship network of co-authors of JungAh Jung

This figure shows the co-authorship network connecting the top 25 collaborators of JungAh Jung. A scholar is included among the top collaborators of JungAh Jung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JungAh Jung. JungAh Jung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Parikh, Sagar V., Scott T. Aaronson, Sanjay J. Mathew, et al.. (2023). Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 49(2). 467–475. 15 indexed citations

Clayton, Anita H., Robert Lasser, Sagar V. Parikh, et al.. (2023). Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial. American Journal of Psychiatry. 180(9). 676–684. 50 indexed citations

Falchook, Gerald S., Xiaofei Zhou, Karthik Venkatakrishnan, et al.. (2015). Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R&D. 16(1). 45–52. 9 indexed citations

Almhanna, Khaldoun, Wells A. Messersmith, Jordi Rodón, et al.. (2014). MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.. Journal of Clinical Oncology. 32(15_suppl). 3546–3546. 7 indexed citations

Goldberg, Stuart L., Pierre Fenaux, Michael Craig, et al.. (2014). An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leukemia Research Reports. 3(2). 58–61. 66 indexed citations

Messersmith, Wells A., Khaldoun Almhanna, Jordi Rodón, et al.. (2013). Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies. Annals of Oncology. 24. iv36–iv36. 2 indexed citations

Almhanna, Khaldoun, Wells A. Messersmith, Jordi Rodón, et al.. (2013). MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.. Journal of Clinical Oncology. 31(15_suppl). TPS3646–TPS3646. 1 indexed citations

Cervantes, Andrés, Élena Elez, Desamparados Roda, et al.. (2012). Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4764–4774. 119 indexed citations

Falchook, Gerald S., John Sarantopoulos, Razelle Kurzrock, et al.. (2011). Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B194–B194. 1 indexed citations

10.

Friedberg, Jonathan W., Daruka Mahadevan, JungAh Jung, et al.. (2011). Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL). Blood. 118(21). 95–95. 34 indexed citations

11.

Goldberg, Stuart L., Pierre Fenaux, Michael Craig, et al.. (2010). Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS). Blood. 116(21). 3273–3273. 18 indexed citations

12.

Jung, JungAh & J. Wanzer Drane. (2007). Survival Instantaneous Log-odds Ratio from Empirical Functions. The International Journal of Biostatistics. 3(1). Article 7–Article 7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact